Drug Trial Radar · NCT03860857
Biomarker Exploration in Aging, Cognition and Neurodegeneration
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
May 1, 2018
Primary completion
Dec 22, 2026
Study completion Dec 22, 2027
Sponsor
- Lead sponsor
- University of California, IrvineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Mar 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this study includes additional PET scans to examine the relationship between tau protein in the brain and cognitive decline. Tau is a protein that is known to form tangles in the areas of the brain important for memory, and these tau tangles are a hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation in the brain using an investigational drug called MK-6240, which is a radio tracer that gets injected prior to a positron emission tomography (PET) scan.
Conditions
- Alzheimer Disease
- Cognitive Impairment
- Cognitive Decline
Interventions
Amyloid PET scanRadiation
Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
Tau PET scan using MK-6240Drug
Tau Positron Emission Tomography scan using radio tracer MK-6240
Neurocognitive testingBehavioral
A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
MRIOther
High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Clinical Dementia Rating - Sum of Box ScoreTime frame: Years 4 and 5 of the grant
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, Irvine
Irvine, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.